Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
|Articles|February 22, 2022
Daily Medication Pearl: Maribavir (Livtencity)
Author(s)Saro Arakelians, PharmD
Maribavir (Livtencity) is indicated for the treatment of adults and pediatric patients with post-transplant cytomegalovirus infection.
Advertisement
Medication Pearl of the Day: Maribavir (Livtencity)
Indication: Maribavir (Livtencity) is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated for the treatment of adults and pediatric patients, 12 years of age and older and weighing at least 35 kg, with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet. CMV is a genus of viruses in the order Herpesvirales, and is related to the viruses that cause chickenpox and infectious mononucleosis.
Insight:
- Dosing: 400 mg (two 200 mg tablets) orally twice daily, with or without food.
- Dosage forms: Tablets 200 mg of maribavir.
- Adverse events: The most common adverse events (all grades, >10%) in subjects treated with maribavir were taste disturbance, nausea, diarrhea, vomiting, and fatigue.
- Mechanism of action: The antiviral activity of maribavir is mediated by competitive inhibition of the protein kinase activity of human CMV enzyme pUL97, which results in inhibition of the phosphorylation of proteins.
- Manufacturer: Takeda
Sources:
Advertisement
Related to this article
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5